Posters, white papers and other resources

Evidence

At Rarity Bioscience we are aiming at radically improving cancer diagnostic. We are developing a technology with the power of saving people’s lives. The technology is time efficient, high sensitive and allow optimal clinical decisions at the right time to improve patient outcome. Our assay technology is based on the groundbreaking discovery of SuperRCA (Prof. Ulf Landegren and Dr. Lei Chen) – here is the evidence.

Publications

Scientific workshop on superRCA at ASH 2023

During the ASH Annual Meeting 2023, Linus Bosaeus showcased the superRCA Mutation Assay in a scientific workshop. The presentation details the technology and its ability to attain a sensitivity of 1 in 100,000 on standard flow cytometers. It also demonstrates how superRCA compares to methods like NGS and ddPCR, detecting molecular MRD 10-100 times more sensitively. The workshop is based on the award winning presentation at ESCCA.

AWARD WINNING PRESENTATION at ESCCA 2023

Lei Chen briefly explains the ultra-sensitive superRCA technology, shows data on sensitivity and performance in comparison with current methods, and uses a patient case to show why it matters in MRD. In the presentation you can see results of testing AML patients using FCM, NGS, ddPCR and Rarity Biosciences ultra-sensitive superRCA. The presentation also suggests why Flow-MRD and superRCA molecular-MRD could be a good match in AML patient monitoring.

New perspective article on Liquid Biopsy using superRCA

From Uppsala University and Karolinska Institute: This perspective article compares existing techniques and the benefits and drawbacks of various types of assays for different applications, and their utility for diagnosis and monitoring. The authors discuss molecular methods for monitoring malignancies, particularly leukemias, and compare them to the super rolling circle amplification, superRCA, technique that enables highly sensitive measurement of mutant sequences using accessible instruments.

Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays

With an innovative, super sensitive technology, so-called superRCA analyzes, any remaining cancer cells can be detected after treatment of acute myeloid leukemia (AML). The method is presented in an article in Nature Communication, this is the technology on which Rarity Bioscience is based and the article describes the application in Leukemia.

Molecular tools to monitor health and disease – and lucky coincidences

”Improved methods for molecular analyses are obviously central for medical research. I will describe herein our work developing tools to reveal molecular states in health and disease. I will recount how I got started in this endeavor, and how our early work characterizing genetic variation led onto high-throughput protein measurements and to techniques for imaging the distribution of proteins and their activity states in tissues. I will also describe a more recent technique to measure even exceedingly rare genetic variants in order to monitor recurrence of disease for tumor patients.”

Posters

MRD poster oraly presented at ESH AML 2023 conference

Anna Robelius, specialist in Hematology at Uppsala University Hospital, presented poster #56 during the ESH AML 2023 conference. The poster demonstrates positive results from a pilot study looking at the utility of using peripheral blood vs. bone marrow for molecular MRD using the ultra-sensitive superRCA assays.

New poster presented at ISMRC conference

CEO Linus Bosaeus, CTO Lei Chen and Dir. BD Alexander Kele attended the ISMRC (International Symposium on Minimal Residual Cancer) Conference in Hamburg, Germany, 2023, to present a new poster. The poster demonstrates initial data from a pilot study looking at the utility of cfDNA mutation detection in low volumes of blood plasma to monitor treatment and residual disease using the ultra-sensitive superRCA assays.

MRD poster presented at AML conference

CEO Linus Bosaeus and co-founder and CTO Dr. Lei Chen presented poster #79 during the AML Conference, to discuss the main topics, such as novel target therapies and markers for Diagnosis and Prognosis. The poster demonstrates positive results from a pilot study looking at the utility of using peripheral blood vs. bone marrow for molecular MRD using the ultra-sensitive superRCA assays.

European Society for Medical Oncology

Dr. Lei Chen presented poster #629P; Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays –winning Best Poster award 2022. The scientific committee pointed out that the data provided new and valuable perspectives for monitoring of Leukemia patients.

Cancer Research conference

Poster presentation by Lei Chen,PhD at the European Association for Cancer Research conference on Liquid Biopsy in Bergamo, Italy. The poster focused on the superRCA single tube assay workflow, the assay sensitivity and precision, followed by multiplex example from colorectal patients.

Nordic Flow Cytometry

Lei Chen, PhD attended the Nordic Flow Cytometry meeting in Oslo where he presented this poster on the topic of Ultra-sensitive monitoring of leukemia patients using SuperRCA mutation detection assays with Flow Cytometer Readout.

Whitepapers

ELC301 translational study

On behalf of the sponsor, Elicera Therapeutics, Rarity is supporting the ELC301 translational study with analysis of the vector copy number (VCN) of integrated retroviral vectors in engineered Human T-cells.